abrdn Life Sciences Investors (NYSE:HQL) Hits New 12-Month High – What’s Next?

abrdn Life Sciences Investors (NYSE:HQL)’s share price hit a new 52-week high on Monday . The company traded as high as $20.20 and last traded at $20.2490, with a volume of 127466 shares. The stock had previously closed at $20.12.

abrdn Life Sciences Investors Stock Performance

The company’s fifty day moving average is $17.88 and its 200-day moving average is $17.22.

abrdn Life Sciences Investors Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Thursday, May 21st were issued a dividend of $0.56 per share. This represents a $2.24 dividend on an annualized basis and a yield of 11.2%. The ex-dividend date was Thursday, May 21st.

Hedge Funds Weigh In On abrdn Life Sciences Investors

A number of institutional investors have recently made changes to their positions in HQL. Geneos Wealth Management Inc. increased its stake in shares of abrdn Life Sciences Investors by 200.1% in the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock worth $29,000 after purchasing an additional 1,529 shares during the period. Global Retirement Partners LLC boosted its stake in abrdn Life Sciences Investors by 187.8% during the 4th quarter. Global Retirement Partners LLC now owns 7,039 shares of the company’s stock valued at $118,000 after purchasing an additional 4,593 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in abrdn Life Sciences Investors during the 4th quarter valued at approximately $177,000. Evolve Private Wealth LLC acquired a new stake in abrdn Life Sciences Investors in the 4th quarter valued at approximately $199,000. Finally, Independent Financial Group LLC acquired a new stake in abrdn Life Sciences Investors in the 1st quarter valued at approximately $211,000. 32.21% of the stock is currently owned by institutional investors.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.